



# The Tumor Board: A behind-the-scenes look

Aaron Weiss, DO  
Associate Professor of Pediatrics  
Tufts University School of Medicine  
Pediatric Hematology-Oncology  
Maine Children's Cancer Program  
[weissa2@mmc.org](mailto:weissa2@mmc.org)







# Tumor Board Definition

- Multidisciplinary treatment planning approach for reviewing and discussing the medical condition and treatment options of a patient

# Background

- No standardized approach to upfront, progressive or recurrent desmoid tumor management
- Opinions of “experts” frequently sought
- Advice often given with limited information regarding the case







# Purpose

Creation of an established scientific forum for discussion of complex desmoid tumor cases

# Sponsorship




- Desmoid Tumor Research Foundation
  - Administrative
  - Financial



# Format

- Regularly scheduled meetings
  - Quarterly
  - Alternating between the first Monday and Wednesday of the month
- Web-based conference platform
  - GoToMeeting
- Core of committed specialists




# Personnel


- Oncology (medical and pediatric)
- Radiology
- Surgical oncology (general and orthopedic)
- Pathology
- Radiation oncology

# Access

- Open to medical personnel (no patients/families)
- International




# Process



- Cases solicited ahead of meeting
- Meeting announcements
- Powerpoint presentation preferred
- Presenting site responsible for providing their own radiology/pathology personnel (if applicable)


# Security



- HIPAA provisions
- Removal of Protected Health Information
  - Name, date of birth, age, date of scans
- Pre-presentation site instructions

**DTRF Virtual Tumour Board Meeting  
Referral Form**

(Please direct any correspondence to Lynne Hernandez [lynne@dtrf.org](mailto:lynne@dtrf.org))  
Enquiries: 215.760.3977



Tumor Board Date		Has Patient Been Previously Presented?	
Patient Initials		Patient Age	
Patient Gender		Date of Diagnosis	
Submitted by		Date	
Site of Primary Tumour			
Clinical Information (Including pertinent imaging findings)			
Clinical trial?			
Surgery		Date(s)	
Radiotherapy		Date(s) and dose(s)	
Hormonal treatment		Date(s)	
TKIs		Date(s)	
Chemotherapy		Date(s) and # of cycles	
Other Treatment		Date(s)	
Local Tumour Board Decision (If applicable, please briefly state outcome of local tumour board discussion)			
Outcome of Virtual Tumour Board Discussion and Recommendations			
Follow-up from Presented Case (Date and Outcome)	For office use only		
		Yes	No
	Added to database?		

**DTRF Virtual Tumor Board Meeting**

Monday, Aug 5th @ 11am ET  
Please direct any correspondence to Lynne Hernandez [lynne@dtrf.org](mailto:lynne@dtrf.org)

**A G E N D A**

**New Patients**

Patient initials	Gender	Local Tumour Board	Treating Oncologist(s)	Clinical Information

**Reviews Post - Primary treatment**

Patient initials	Gender	Local Tumour Board	Treating Oncologist(s)	Clinical Information



# Mock Tumor Board




# Case Presentation


- 3 year old male with several months of left facial swelling
- Evaluated by pediatrician, dentist, ENT, craniofacial surgeon




# Imaging




- CT Neck with Contrast (March 2019)
  - Expansile lesion involving the left jaw with destruction of the bone with a soft tissue component extending into the floor of the mouth. Overall the lesion measures 2.9 cm x 5.2 cm x 3.4 cm



# Imaging





- MRI Neck W/WO Contrast (April 2019)




# Pathology


- Biopsy of mass (April 2019) followed by debulking surgery
- Genomic findings
  - *CTNNB1* mutation (T41A)



20x low magnification H&E



100X High magnification H&E  
Higher power in a more cellular area of infiltrating fibroblasts.




Nuclear staining with Beta Catenin immunostain


# Case Presentation



- Currently 4 months following surgery
- Surgical complications: some nerve deficits and limitations opening mouth
- Follow up MRI in July with significant for decrease in size of left jaw lesion (4 cm x 1.5 cm compared to 5.3 cm x 2.2 cm)




# Questions for the Group



- Systemic vs local therapy vs combination vs observation?
- Which systemic therapy?
  - Cytotoxic therapy:
    - Methotrexate/vinblastine(vinorelbine), doxorubicin
  - Non-cytotoxic therapy:
    - Tyrosine kinase inhibitor (sorafenib, pazopanib), hormonal therapy (NSAID, tamoxifen), hydroxyurea, mTOR inhibitors
- Which local therapy?
  - Surgery
  - Radiation – photon/proton
  - Interventional radiology – cryo- vs radiofrequency ablation

# Tumor Board Recommendations



## DTRF Virtual Tumour Board Meeting Referral Form

(Please direct any correspondence to Lynne Hernandez [lynne@dtrf.org](mailto:lynne@dtrf.org))  
Enquiries: 215.760.3977


<b>Local Tumour Board Decision</b> (If applicable, please briefly state outcome of local tumour board discussion)	<b>Surgical excision followed by conservative observation</b>		
<b>Outcome of Virtual Tumour Board Discussion and Recommendations</b>	<p>Pt has undergone debulking surgery. The most recent MRI from the beginning of July shows macroscopic residual disease.</p> <p>MDM recommendation: In view of the site and high risk of progression the recommendation was for treatment rather than observation. In the first instance conventional treatment with combination methotrexate and vinorelbine/vinblastine should be considered.</p> <p>It was suggested review of the imaging with interventional radiologist to exclude the option of ablation/RFA of the lesion.</p>		
<b>Follow-up from Presented Case (Date and Outcome)</b>	<b>For office use only</b>		
		<b>Yes</b>	<b>No</b>
	<b>Added to database?</b>		

# Virtual Desmoid Tumor Board Mission



- Multidisciplinary
- Resourceful
- Inclusive
- Collaborative

# Meeting Statistics



- Inaugural tumor board: December 6, 2017
- Number of cases presented:
  - 2017: 2
  - 2018: 15
  - 2019: 11 +
- Participating countries
  - United States, India, Portugal, England, Australia, Iran



# Acknowledgements

- **Marlene, Jeanne and Lynne (DTRF)**
- Rob Lefkowitz (radiology)
- Matt van de Rijn (pathology)
- Robert Benjamin (medical oncology)
- Palma Dileo (medical oncology)
- Alessandro Gronchi (surgery)



**Lynne: the woman behind the curtain**

# Interested in Have Your Case Presented?



Next: Wednesday November 6, 2019

Lynne Hernandez: [lynne@dtrf.org](mailto:lynne@dtrf.org)